Vistagen Therapeutics

VTGN · NASDAQ

$0.1978−$0.0053 (−2.61%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $0.2031

Latest news

Press releaseOct 20, 8:30 AM ETGlobe Newswire
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
Press releaseSep 24, 7:00 AM ETGlobe Newswire
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
NewsSep 23, 9:25 AM ETVandana Singh
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Press releaseSep 22, 8:30 AM ETGlobe Newswire
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Press releaseAug 14, 8:32 AM ETGlobe Newswire
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Press releaseAug 6, 8:30 AM ETGlobe Newswire
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Press releaseAug 4, 5:00 AM ETGlobe Newswire
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
Press releaseJul 31, 8:30 AM ETGlobe Newswire
Vistagen Appoints Douglas J. Williamson to its Board of Directors
NewsJun 30, 1:35 PM ETVandana Singh
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
NewsJun 30, 12:08 PM ETAvi Kapoor
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
NewsJun 30, 9:47 AM ETAvi Kapoor
US Stocks Mixed; Home Prices Increase 1.1% In April
NewsJun 30, 8:09 AM ET
Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary Endpoint
Press releaseJun 30, 8:00 AM ETBusiness Wire
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Press releaseJun 15, 4:30 PM ETBusiness Wire
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Press releaseJun 9, 8:30 AM ETBusiness Wire
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Press releaseJun 1, 2:40 PM ETPRNewswire
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Press releaseMay 27, 8:30 AM ETBusiness Wire
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
Press releaseMay 19, 8:30 AM ETBusiness Wire
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Press releaseMay 14, 8:30 AM ETBusiness Wire
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Press releaseMay 12, 7:30 AM ETBusiness Wire
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Press releaseMay 8, 7:30 AM ETBusiness Wire
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Press releaseApr 28, 9:00 AM ETPRNewswire
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop
Press releaseApr 22, 8:30 AM ETBusiness Wire
Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
Press releaseMar 17, 3:49 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
Press releaseMar 16, 4:00 PM ETGlobe Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen Therapeutics, Inc. Lawsuit – VTGN
Press releaseMar 16, 11:09 AM ETBusiness Wire
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight
Press releaseMar 16, 5:00 AM ETPRNewswire
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
Press releaseMar 13, 9:00 AM ETGlobe Newswire
VTGN Shareholder Alert: Vistagen Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
Press releaseMar 12, 9:10 AM ETGlobe Newswire
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
Press releaseMar 11, 9:01 AM ETPRNewswire
VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
Press releaseMar 11, 9:00 AM ETPRNewswire
LEVI & KORSINSKY, LLP ADVISORY TO INSTITUTIONAL INVESTORS: CLASS ACTION AGAINST VISTAGEN THERAPEUTICS MAY IMPACT PORTFOLIO HOLDINGS
Press releaseMar 11, 9:00 AM ETPRNewswire
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact Levi & Korsinsky
Press releaseMar 10, 3:30 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
Press releaseMar 10, 9:00 AM ETPRNewswire
Contact The Gross Law Firm by March 16, 2026 Deadline to Join Class Action Against Vistagen Therapeutics, Inc.(VTGN)
Press releaseMar 9, 4:00 PM ETGlobe Newswire
Vistagen Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 16, 2026 to Discuss Your Rights – VTGN
Press releaseMar 6, 4:00 PM ETGlobe Newswire
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) Seeking Recovery for Investors – Contact The Gross Law Firm
Press releaseMar 5, 4:57 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTGN
NewsMar 5, 10:38 AM ETVandana Singh
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints
NewsFeb 13, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsFeb 12, 4:32 PM ET
Vistagen Therapeutics Earnings Report: Q3 Overview
NewsFeb 12, 6:11 AM ET
Earnings Scheduled For February 12, 2026
NewsDec 17, 12:02 PM ETAvi Kapoor
Crude Oil Rises Over 1%; General Mills Earnings Top Views
NewsDec 17, 9:39 AM ETAvi Kapoor
Dow Jumps 150 Points; Jabil Posts Upbeat Earnings
NewsNov 17, 4:07 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsNov 13, 6:11 AM ET
Earnings Scheduled For November 13, 2025
NewsNov 12, 1:03 PM ET
Examining the Future: VistaGen Therapeutics's Earnings Outlook
NewsAug 7, 4:33 AM ET
Earnings Scheduled For August 7, 2025
NewsAug 6, 5:02 PM ET
Insights Ahead: VistaGen Therapeutics's Quarterly Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Nasdaq Gains Over 300 Points; Chicago PMI Falls In June

US Stocks Mixed; Home Prices Increase 1.1% In April

Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary Endpoint

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop

Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen Therapeutics, Inc. Lawsuit – VTGN

CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight

VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

VTGN Shareholder Alert: Vistagen Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm

VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

LEVI & KORSINSKY, LLP ADVISORY TO INSTITUTIONAL INVESTORS: CLASS ACTION AGAINST VISTAGEN THERAPEUTICS MAY IMPACT PORTFOLIO HOLDINGS

Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) - March 16, 2026 Deadline to Join - Contact Levi & Korsinsky

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

Contact The Gross Law Firm by March 16, 2026 Deadline to Join Class Action Against Vistagen Therapeutics, Inc.(VTGN)

Vistagen Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 16, 2026 to Discuss Your Rights – VTGN

Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN) Seeking Recovery for Investors – Contact The Gross Law Firm

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTGN

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

12 Health Care Stocks Moving In Friday's Pre-Market Session

Vistagen Therapeutics Earnings Report: Q3 Overview

Earnings Scheduled For February 12, 2026

Crude Oil Rises Over 1%; General Mills Earnings Top Views

Dow Jumps 150 Points; Jabil Posts Upbeat Earnings

12 Health Care Stocks Moving In Monday's After-Market Session

Earnings Scheduled For November 13, 2025

Examining the Future: VistaGen Therapeutics's Earnings Outlook

Earnings Scheduled For August 7, 2025

Insights Ahead: VistaGen Therapeutics's Quarterly Earnings